Ms Kathy He
- CEO, Lerna Biopharma Pte.
Kathy He is the Chief Executive Officer of Lerna Biopharma Pte, an innovative biotech leveraging novel biology insights and proprietary siRNA platform to develop highly targeted and potent nucleic acid therapeutics for liver diseases. Ms. He has over 20 years of R&D and commercial experience from global pharma companies such as Abbott, Merck and Takeda, notably in building differentiated product portfolios, developing strategic opportunities, and successfully bringing innovative therapeutics to market.
Prior to joining Lerna, Ms. He was the Chief Business Officer (CBO) and General Manager at Kira Pharmaceuticals, where she led the closing of its $60M Series B+ round of financing and built an operation in China to support Kira’s global expansion. Before Kira, she was the CBO and Head of Corporate Development at Abbisko Therapeutics (HKEx stock code: 02256), where she led the raise of over $100M and closed a series of cross-border strategic partnerships. In addition to her extensive operating experience, Kathy also worked as a Venture Partner and Managing Director at top tier investment firms in China.
Kathy received a BS degree in biology from Wuhan University, a MS in molecular biology from University of Illinois at Urbana-Champaign, and MBA from Kellogg School of Management at Northwestern University. She is currently a board member of Diagnostic Photonics, an innovative medical device company, a former trustee of Illinois Mathematics and Science Academy, and a past board member of the BayHelix Group, a non-profit professional organization for business leaders in life sciences and healthcare industries.